Drug: Osimertinib (Tagrisso, AstraZeneca)
Status: Approved for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation–positive non-small cell lung cancer, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy
Significant Information:
- Based on data from the Phase III AURA3 trial that demonstrated significant improvement in progression-free survival (PFS) with osimertinib compared with